Pfizer reports positive top-line data for Trumenba Phase II study in adolescents
US pharma giant Pfizer (NYSE: PFE) has announced positive top-line results of a Phase II study of Trumenba (meningococcal group b vaccine) co-administered with FDA-approved, routine meningococcal and single-dose tetanus, diphtheria and pertussis vaccines.
The study of more than 2,600 healthy individuals of 10-12 years of age met its co-primary immunogenicity objectives regarding co-administration of Trumenba with the other vaccines.
Data from a recently completed Phase III study also demonstrated the safety and tolerability of the drug in approximately 5,600 healthy individuals aged 10 to 25, and were consistent with data from studies supporting the October 2014 accelerated approval of Trumenba in the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze